WO2000077246A3 - A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS - Google Patents

A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS Download PDF

Info

Publication number
WO2000077246A3
WO2000077246A3 PCT/DK2000/000316 DK0000316W WO0077246A3 WO 2000077246 A3 WO2000077246 A3 WO 2000077246A3 DK 0000316 W DK0000316 W DK 0000316W WO 0077246 A3 WO0077246 A3 WO 0077246A3
Authority
WO
WIPO (PCT)
Prior art keywords
activity
fviia
identifying
fvii
drug candidate
Prior art date
Application number
PCT/DK2000/000316
Other languages
French (fr)
Other versions
WO2000077246A2 (en
Inventor
Palle Jakobsen
Egon Persson
Original Assignee
Novo Nordisk As
Palle Jakobsen
Egon Persson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Palle Jakobsen, Egon Persson filed Critical Novo Nordisk As
Priority to AU50621/00A priority Critical patent/AU5062100A/en
Priority to JP2001503687A priority patent/JP2003530819A/en
Priority to EP00934951A priority patent/EP1192270A2/en
Priority to US09/616,010 priority patent/US6238878B1/en
Publication of WO2000077246A2 publication Critical patent/WO2000077246A2/en
Publication of WO2000077246A3 publication Critical patent/WO2000077246A3/en
Priority to US09/844,828 priority patent/US6444434B1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Abstract

The invention relates to compounds inhibiting the activation of FX to FXa by TF/FVIIa. The compounds are anticoagulants. The invention also relates to a method of identifying a drug candidate.
PCT/DK2000/000316 1999-06-14 2000-06-13 A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS WO2000077246A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU50621/00A AU5062100A (en) 1999-06-14 2000-06-13 Fviia/tf activity inhibiting compounds
JP2001503687A JP2003530819A (en) 1999-06-14 2000-06-13 FVIIa / TF activity inhibiting compounds
EP00934951A EP1192270A2 (en) 1999-06-14 2000-06-13 FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
US09/616,010 US6238878B1 (en) 1999-06-14 2000-07-13 FVlla/TF activity inhibiting compounds
US09/844,828 US6444434B1 (en) 1999-06-14 2001-04-27 FVIIa/TF activity inhibiting compounds

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
DKPA199900840 1999-06-14
DKPA199900840 1999-06-14
US13971499P 1999-06-17 1999-06-17
US60/139,714 1999-06-17
DKPA199900910 1999-06-25
DKPA199900910 1999-06-25
US14141699P 1999-06-29 1999-06-29
US60/141,416 1999-06-29
DKPA199901241 1999-09-03
DKPA199901241 1999-09-03
US15286399P 1999-09-08 1999-09-08
US60/152,863 1999-09-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/616,010 Continuation US6238878B1 (en) 1999-06-14 2000-07-13 FVlla/TF activity inhibiting compounds

Publications (2)

Publication Number Publication Date
WO2000077246A2 WO2000077246A2 (en) 2000-12-21
WO2000077246A3 true WO2000077246A3 (en) 2001-02-22

Family

ID=27220957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000316 WO2000077246A2 (en) 1999-06-14 2000-06-13 A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS

Country Status (5)

Country Link
US (2) US6238878B1 (en)
EP (1) EP1192270A2 (en)
JP (1) JP2003530819A (en)
AU (1) AU5062100A (en)
WO (1) WO2000077246A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018398A1 (en) 1998-09-25 2000-04-06 Sunol Molecular Corporation Pharmaceutically active compounds and methods of use thereof
AU5062100A (en) * 1999-06-14 2001-01-02 Novo Nordisk A/S Fviia/tf activity inhibiting compounds
WO2001030333A2 (en) * 1999-10-27 2001-05-03 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof
EP1829535A3 (en) * 1999-10-27 2007-10-24 Tanox, Inc. Tissue factor antagonists and methods of use thereof
DE60132484T2 (en) * 2000-11-02 2009-01-15 Nippon Shinyaku Co., Ltd. CHINAZOLINE DERIVATIVES AND MEDICAMENTS
EP1446140A4 (en) 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US7868028B2 (en) * 2002-06-17 2011-01-11 Fred Drasner Guanidine compounds as anesthetics and for treatment of nervous system disorders
AU2003258662A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
AU2005244249A1 (en) * 2004-03-17 2005-11-24 Novartis Vaccines And Diagnostics, Inc. Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
US20080254043A1 (en) * 2005-02-07 2008-10-16 Chugai Seiyaku Kabushiki Kaisha National University Corporation Hamamatsu Drug For Treating Ischemic Disease
EP1918718A1 (en) * 2006-10-31 2008-05-07 Roche Diagnostics GmbH Methods and devices for electrochemical determination of factor Xa inhibitors in blood samples
US7724502B2 (en) * 2007-09-04 2010-05-25 Avx Corporation Laser-welded solid electrolytic capacitor
EP2294183B1 (en) 2008-06-18 2015-12-16 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
BRPI0922884A2 (en) 2008-12-08 2018-11-06 Boehringer Ingelheim Int cancer treatment compounds
PL2552959T3 (en) 2010-03-26 2017-08-31 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
US9133239B2 (en) 2010-04-20 2015-09-15 The Research Foundation For The State University Of New York Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
US10201589B2 (en) 2013-12-11 2019-02-12 University Of Massachusetts Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA)
WO2016149485A1 (en) 2015-03-17 2016-09-22 The Regents Of The University Of California Novel chemoimmunotherapy for epithelial cancer
EP4247408A1 (en) 2020-11-20 2023-09-27 UNIVERSITÄTSmedizin der Johannes Gutenberg- Universität Mainz Inhibitors of the tissue factor-protease activated receptor 2 (tf-par2) signaling pathway for use in the treatment or prevention of heart failure (hf) and associated or resulting diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007432A1 (en) * 1989-11-13 1991-05-30 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides
WO1995000541A1 (en) * 1993-06-18 1995-01-05 Hafslund Nycomed A/S Factor vii-derived peptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500309A (en) 1982-05-07 1985-02-19 The Kansas University Endowment Association Method for regional anticoagulation during extracorporeal dialysis
DE3572179D1 (en) 1984-09-21 1989-09-14 Boehringer Ingelheim Int Blood coagulation inhibiting proteins, process for preparing them and their use
CA1265446A (en) 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
DE19538716A1 (en) * 1995-10-18 1997-04-24 Behringwerke Ag Method for quantification of activated coagulation factor VII (FVIIa)
AU5062100A (en) * 1999-06-14 2001-01-02 Novo Nordisk A/S Fviia/tf activity inhibiting compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007432A1 (en) * 1989-11-13 1991-05-30 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides
WO1995000541A1 (en) * 1993-06-18 1995-01-05 Hafslund Nycomed A/S Factor vii-derived peptides

Also Published As

Publication number Publication date
US6444434B1 (en) 2002-09-03
US6238878B1 (en) 2001-05-29
EP1192270A2 (en) 2002-04-03
JP2003530819A (en) 2003-10-21
AU5062100A (en) 2001-01-02
WO2000077246A2 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
WO2000077246A3 (en) A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
GB2370052B (en) Assembly, method and system for isolating a region of a well
DK1007092T3 (en) A method for inhibiting complement activation via the alternative pathway
IT1299705B1 (en) GUIDANCE AND REFERENCE STRUCTURE, PARTICULARLY FOR LACES.
WO2002045524A3 (en) Prolyl endoprotease from aspergillus niger
TR199600126A1 (en) Naftil compounds, intermediates, compounds and methods.
EP1118322A4 (en) Drugs for improving vesical excretory strength
MX257124B (en) A method for the start-up of an epoxidation process, a catalyst and a process for the epoxidation of an olefin.
WO2001097809A3 (en) Method of treating cardiovascular disease using rapamycin
ZA200100795B (en) Computer automated system for management of engineering drawings.
WO2002034201A3 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
WO2001006261A3 (en) Screening for therapeutic agents being scap antagonists
BR0110689B1 (en) fungicidal composition, and methods for enhancing the fungicidal activity of etaboxam, and for controlling unwanted phytopathogens.
EP1262556A3 (en) Antimicrobial peptides and method for identifying and using such peptides
WO2003038444A3 (en) Biomarkers of liver function
ITMI20031064A1 (en) PROCEDURE FOR THE MANEUVER OF A PARKING BRAKING SYSTEM OF AN ELECTROMECHANICAL BRAKING SYSTEM PRESENTING A PARKING BRAKING SYSTEM AND A WORKING BRAKING SYSTEM, AND ELECTROMAGNETIC BRAKING SYSTEM.
WO2001046455A3 (en) Survivin promotion of angiogenesis
BR0005204B1 (en) spiral machine, spiral member and method of manufacturing a spiral member.
EP1325920A4 (en) N-substituted benzothiophenesulfonamide derivatives
TR199901383A3 (en) Process and intermediates for the production of pyridine-2,3-dicarboxylate compounds.
WO2007010013A3 (en) Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
EP1486494A4 (en) N-substituted benzothiophenesulfonamide derivative
WO1999015894A3 (en) Method of identification of leads or active compounds
ZA200103855B (en) Method, system and computer program for auditing financial plans.
WO2000014254A3 (en) Component of bromelain

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09616010

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000934951

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 503687

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000934951

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000934951

Country of ref document: EP